Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1625)	1/13/2016 10:20:20 AM
From: eico20	Read Replies (1) \| Respond to of 2026

the first offering isn't much, question is when is the 2nd much larger the initial closing to occur on or about January 13, 2016 and to include gross proceeds of approximately $2.2 million from the sale of 2,528,411 shares of common stock and warrants to purchase up to 1,264,204 shares of common stock.

To: phoenix_rising who wrote (1625)	1/13/2016 10:37:39 AM
From: Mirror Image	Read Replies (1) \| Respond to of 2026

Yeah, well they had to find a way to squeeze the retail shareholder out of it. I guarantee you many were expecting a quick flip. Now - who knows. Those who did that are going to be the weaker hands - who they might be wanting to take advantage of. As Eicoman states - the initial offering is not that many shares. What I would point out is the old Sarissa warrants now have an exercise price of .88 instead of $1.82. As we all know. It's going to all be about the Fispemifene results in a couple months. Now that the company does have a little cushion - we will see what happens when those results come out. And Yes - if those results are bad - We are royally screwed - for a year or two ( we would see a lot more dilution than what that filing has - at low prices ).